# Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/AZYO/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-c5c3be7a
Ticker: AZYO
Company: Aziyo Biologics
Source: Aziyo Biologics
Published: 2026-05-18 20:05 EST
Original Source URL: https://investors.elutia.com/news-releases/news-release-details/elutia-announces-grants-inducement-awards-under-nasdaq-listing-0
## Summary

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc.

## Article Body
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”). The award was approved by the independent Compensation Committee of the Board of Directors and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Under the Plan, the one new employee received an aggregate of 48,000 non-qualified stock options (the “Options”). The Options vest 25% on the first anniversary of the vesting commencement date, with the balance vesting in equal monthly installments over the following three years. Vesting is subject to each recipient’s continued employment through the applicable vesting date. The Option had an exercise price of $1.05 per share, the closing price of Elutia’s common stock on the Nasdaq Capital Market on May 13, 2026, the grant date. The Options are subject to the terms and conditions of the Plan and the applicable stock option agreement.

About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com .

Investors: Elutia Investor Relations ir@elutia.com
## Recent Company News
- 2026-07-16 20:05 EST — [Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch](https://biopharmsignal.com/news/AZYO/elutia-signs-definitive-agreement-to-sell-simpliderm-in-transaction-valued-at-up-fa42185e) — Source: Aziyo Biologics
- 2026-06-11 20:05 EST — [Elutia to Present at Planet MicroCap Showcase 2026 on June 17th](https://biopharmsignal.com/news/AZYO/elutia-to-present-at-planet-microcap-showcase-2026-on-june-17th-52191312) — Source: Aziyo Biologics
- 2026-05-18 20:05 EST — [Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AZYO/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-c5c3be7a) — Source: Aziyo Biologics
- 2026-05-14 20:06 EST — [Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market](https://biopharmsignal.com/news/AZYO/elutia-reports-first-quarter-2026-results-and-highlights-nxt-41x-progress-toward-1-5-billion-u-s-plastic-and-reconstructive-surgery-market) — Source: Aziyo Biologics
- 2026-05-14 20:01 EST — [Elutia to Present at the 16th Annual LD Micro Invitational on May 18th](https://biopharmsignal.com/news/AZYO/elutia-to-present-at-the-16th-annual-ld-micro-invitational-on-may-18th) — Source: Aziyo Biologics
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)